{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T21:31:01Z","timestamp":1783373461365,"version":"3.54.6"},"reference-count":12,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaip.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:56:42Z","timestamp":1777597002000},"page":"1525-1528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1811-9267","authenticated-orcid":false,"given":"Kittipos","family":"Visitsunthorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Koneti","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2026.03.040_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaci.2023.11.004","article-title":"Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): a proposed approach to redefining ALPS and other lymphoproliferative immune disorders","volume":"153","author":"Magerus","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.040_bib2","series-title":"GeneReviews","article-title":"Activated PI3K delta syndrome","author":"Sacco","year":"1993"},{"key":"10.1016\/j.jaip.2026.03.040_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/hematology.2024000537","article-title":"Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase delta syndrome","volume":"2024","author":"Rao","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jaip.2026.03.040_bib4","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1016\/j.cell.2025.05.037","article-title":"Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment","volume":"188","author":"Walsh","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2026.03.040_bib5","article-title":"Natural history of clinical manifestations in activated phosphoinositide 3-kinase delta syndrome (APDS): time-to-event analyses using the European Society for Immunodeficiencies-APDS registry","volume":"283","author":"Maccari","year":"2025","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.040_bib6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"Acs Med Chem Lett"},{"key":"10.1016\/j.jaip.2026.03.040_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2026.03.040_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2026.03.040_bib9","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2018-99-113426","article-title":"Safety and efficacy of long term suppression of PI3Kinase pathway by small molecule PI3K-delta inhibitor, leniolisib in APDS (activated PI3K\u03b4 syndrome)","volume":"132","author":"Rao","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2026.03.040_bib10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3Kd inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2026.03.040_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","article-title":"PI3Kdelta pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3Kdelta syndrome and beyond","volume":"12","author":"Cant","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2026.03.040_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219826003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:53:38Z","timestamp":1783331618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219826003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2213219826003272"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.040","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shrinking Spleens and Nodes, Expanding Horizons: Leniolisib and the Future of Activated Phosphoinositide 3-Kinase Delta Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}